SUMMAR\'. Abnormalities of calcium homeostasis are a recognized feature of endstage renal disease. The treatment of choice is renal transplantation, but this does not always result in normalization of the biochemical profile, Persistent hypercalcaemia is well documented and our study was undertaken to investigate the status of the calcium regulating hormones in renal patients post-transplantation.
Patients with end-stage renal disease develop a number of metabolic disturbances including abnormalities of calcium homeostasis. In the classical trade-off theory of Bricker,1 the loss of nephrons and fall in glomerular filtration rate (GFR) associated with progressive renal disease produces a rise in plasma phosphate and, by decreasing the ionized fraction of plasma calcium, and inhibiting the synthesis of l,25-dihydroxyvitarnin D, stimulates parathyroid hormone (PTH) release.
In early or moderate chronic renal failure the plasma phosphate is not, however, elevated-and the 1,25(OHh D concentration does not fall until the renal failure is well established.' The current view is that the trade-off of the secondary hyperparathyroidism is to maintain a normal plasma 1,25(OHh D concentration and not phosphate homeostasis. Elevated plasma PTH concentrations have been identified in early renal failure despite a lack of fasting or post-prandial hyperphosphataemia and the negative feedback of 1,25(OHhD is a more important stimulus to parathyroid gland activity than hypocalcaemia." The finding of normal plasma 1,25(OHhD concentrations in early renal failure therefore Correspondence: Dr Angela Fairney. needs to be explained. Evidence indicates that the levels of 1,25(OH)2D are kept within the normal range by raised PTH concentrations as a result of the feedback relationship between the two hormones.
A number of measures aimed at preventing renal osteodystrophy are employed in patients with end-stage renal disease but the treatment of choice for this condition is renal transplantation which should reverse the associated metabolic changes.
Hypercalcaemia was documented in some of our renal transplant patients, so the biochemical status of patients attending the renal transplant clinic at St Mary's Hospital was investigated in order to study this finding in more detail.
METHODS

Patients and samples
Blood samples were obtained from 100 consecutive patients attenting the St Mary's Hospital Renal Transplant Clinic during a 10 week period. All patients (mean age 43 years, range 22-68 years) had functioning renal grafts and the mean time elapsed since transplantation was 63 months (range 1-270 months). Immunosuppression was maintained with prednisolone and cyclosporin A or azothiaprine, and all patients ate a normal diet and did not receive vitamin D supplementation. A 10 mL lithium heparin sample was obtained for general biochemical assessment including calcium, albumin, phosphate, alkaline phosphatase and creatinine, and a 10 mL clotted sample was taken for the measurement of 1,25(OHhD, intact PTH and osteocalcin. As biochemical evaluation is part of the routine follow up of renal transplant patients Ethical Committee approval was not considered necessary. Serum for 1,25(OH)2D, intact PTH and osteocalcin was separated by centrifugation at 780 x g for 5 min within 3 h of venipuncture and stored at -20 DC for later analysis.
Biochemical analyses 1,25(OHhD was measured by the Incstar calf thymus radioreceptor assay (lncstar Ltd, Wokingham, UK) which has a lower limit of detection of 8 pg/mL and a between-batch coefficient of variation (CV) of 12'80/0. Intact-PTH was measured using the Incstar N-tact PTH immunoradiometric assay (lncstar Ltd, Wokingham, UK) which has a lower limit of detection of 1· 8 pg/mL and a between-batch CV at 10 and 979pg/mL of 10·8% and 6'3%, respectively. Osteocaicin was measured in selected samples using the CIS human osteocalcin radioimmunoassay kit (CIS UK Ltd, High Wycombe, UK) which has a lower limit of detection of 1· 1 ng/mL and a between-batch CV at lOng/mL of 10·9%. Serum PTH concentrations were elevated (>55 pg/mL) in 51 (55%) of the patients (Fig. 1) . Only four patients (5%) were hypercaicaemic (adjusted calcium> 2· 60 mmol/L). There was no correlation between the elevated PTH values and the adjusted calcium concentrations (r= 0'08, ns) or between the serum 1,25(OHhD and PTH concentrations (r= -0'03, ns). Time since transplantation did not correlate with any of the analytes investigated, especially the 1,25(OHh D and PTH concentrations. There was a weak Sufficient serum was available to measure osteocalcin concentrations in 67 patients (Fig. 1) . There was a significant positive relationship between log osteocalcin and log PTH concentrations ( Fig. 2; r=0 '61, P<O·OOI). There was also a significant positive correlation between log osteocalcin and log alkaline phosphatase (r=0'50, P<O·OOI). ours. They found 10' 5% of 95 patients to be hypercalcaemic on the basis of total calcium measurements. When ionized calcium was used, however, 49' 5% of their patients were hypercalcaemic. Ionized calcium was not measured in our study so it is possible that the true prevalence of hypercalcaemia is much greater than that detected.
RESULTS
All our hypercalcaemic patients had raised serum PTH concentrations, but 47 individuals were normocalcaemic despite having significantly elevated PTH levels, and there was no correlation between the degree of hypercalcaemia and the PTH concentration. In 1973 David et al. 8 commented that the PTH level in the hypercalcaemic group was higher than expected for the degree of hypercalcaemia, but this may have been a reflection of the PTH assay used 20 years ago. It is now known that renal failure nullifies the value of results from older PTH assays;" Absence of ionized calcium measurement has probably underestimated the number of patients with hypercalcaemia. In a study investigating the suppressibility of PTH by calcium in haemodialysis patients the ionized calcium was raised while the total calcium remained normal in patients with biochemical hyperparathyroidism.l" The question remains, however, whether the PTH measured in renal transplant patients by immunological methods reflects bioactive PTH.
Osteocalcin, a vitamin K dependent protein released by stimulated osteoblasts, has been shown to be elevated in states of increased bone turnover such as hyperparathyroidism.'? If the PTH measured in renal transplant patients is bioactive there should be increased osteoblastic activity and, hence, elevated osteocalcin concentrations. When osteocalcin was measured in 67 of our patients the log values correlated positively with log PTH concentrations (r= 0'61, p<O·OOI). There was also a weaker relationship (r = 0 . 50, P < 0 . 001) between log osteocalcin and log alkaline phosphatase, findings which suggest that the measured PTH is bioactive.
The continued hyperparathyroidism after renal transplantation may be related to the slow involution of the glands" which are known to become hyperplastic with renal failure. 1,25(OHh D decreases the transcription of the pre-proparathyroid hormone gene," thus the low 1,25(OHh D concentrations of renal failure could be another contributory factor. This cannot, however, be the whole story as, in our series, biochemical hyper-parathyroidism is twice 
Jl
The treatment of choice for end-stage renal disease is kidney transplantation as this should reverse the associated metabolic changes. In our study 20070 of 92 renal transplant patients had low serum 1,25(OHh D concentrations ( < 16 pg/mL) while 55% maintained elevated PTH concentrations (>55 pg/mL). Only 5% of the patients were persistently hypercalcaemic (adjusted calcium > 2· 60 mmollL) and in all cases this was mild (adjusted calcium < 3· 00 mmollL).
Although pre-transplantation data were not available for our patients the post-transplantation serum 1,25(OHhD concentrations showed broad agreement with other published studies.t-" Hypercalcaemia, however, proved to be less prevalent than in previously published series which have reported persistent hypercalcaemia in approximately one third of their patients.":'? More recent studies found a 20% prevalence in transplant recipients I 1-13 but only Conceicao et al. 14 have identified a percentage approaching as common as reduced 1,25(OHhD concentrations. If the prevalence of hyperparathyroidism exceeds that of hypercalcaemia even when ionized calcium is measured it is possible that there may be some alteration in the PTH receptor itself, in its responsiveness or in its numbers such that hyperparathyroidism does not necessarily result in hypercalcaemia in renal transplant patients.
